VEGFR-2-IN-73 

VEGFR-2-IN-73 is a potent and selective VEGFR-2 inhibitor, showing selectively inhibition of VEGFR-2 (IC₅₀ = 0.0787 μM) over EGFR (IC₅₀ = 1.31 μM). VEGFR-2-IN-73 demonstrates potent antiproliferative activity across multiple cancer cell lines. VEGFR-2-IN-73 induces G2/M and Pre-G1 phase arrest and significantly enhances apoptosis. VEGFR-2-IN-73 can be used in cancer research, such as colorectal carcinoma, hepatocellular carcinoma, and breast cancer^[1].

VEGFR-2-IN-73 (compound 15) (2 days) displays strong cytotoxicity against HCT-116, HepG-2, and MCF-7 Cell Lines (IC₅₀ = 3.66, 3.31, and 4.29 μM, respectively), while showing minimal cytotoxicity against normal WI-38 cells (IC₅₀ > 69 μM), demonstrating a favorable selectivity profile^[1].
VEGFR-2-IN-73 (3.31-4.29 μM, 72 h) effectively induces cell cycle arrest at both the G2/M and Pre-G1 phases, and significantly triggers apoptosis in HCT-116, HepG-2, and MCF-7 Cells, with effects comparable to those of Doxorubicin (HY-15142A)^[1].
VEGFR-2-IN-73 possesses a superior binding affinity for VEGFR-2 (predicted binding energy: -24.27 kcal/mol) compared to the reference inhibitor Sorafenib (HY-10201) (-20.88 kcal/mol)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

559.70

C₂₉H₂₉N₅O₃S₂

C/C(C1=CC=C(C=C1)S(=O)(N2CCC(CC2)C)=O)=N/N=C3SC(C(C4=CC=CC=C4)=O)=NN\3C5=CC=CC=C5

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Al-Ziyadi SH, et al. Novel Sulfonamide Derivatives as Anticancer Agents, VEGFR‑2 Inhibitors, and Apoptosis Triggers: Design, Synthesis, and Computational Studies. ACS Omega. 2025 Aug 25;10(35):39772-39790.  [Content Brief]